Voyager Therapeutics, Inc. (VYGR)
NASDAQ: VYGR · Real-Time Price · USD
3.785
+0.065 (1.75%)
Aug 15, 2025, 10:48 AM - Market open
Voyager Therapeutics Employees
Voyager Therapeutics had 172 employees as of December 31, 2024. The number of employees increased by 10 or 6.17% compared to the previous year.
Employees
172
Change (1Y)
10
Growth (1Y)
6.17%
Revenue / Employee
$247,558
Profits / Employee
-$627,523
Market Cap
209.95M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 172 | 10 | 6.17% |
Dec 31, 2023 | 162 | 37 | 29.60% |
Dec 31, 2022 | 125 | 24 | 23.76% |
Dec 31, 2021 | 101 | -78 | -43.58% |
Dec 31, 2020 | 179 | -7 | -3.76% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
VYGR News
- 8 days ago - Voyager Reports Second Quarter 2025 Financial and Operating Results - GlobeNewsWire
- 4 weeks ago - Voyager Adds Fourth Wholly-Owned Alzheimer's Disease Program to Pipeline, Complementing Existing Tau and Amyloid Assets with New APOE Approach - GlobeNewsWire
- 2 months ago - Voyager to Present at H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference - GlobeNewsWire
- 3 months ago - Voyager Demonstrates ALPL Receptor-Mediated Blood-Brain Barrier Transport of Novel AAV Capsids in Molecular Therapy Publication - GlobeNewsWire
- 3 months ago - Voyager Reports First Quarter 2025 Financial and Operating Results - GlobeNewsWire
- 3 months ago - Voyager Next-Generation CNS Capsids Featured at ASGCT 28th Annual Meeting - GlobeNewsWire
- 4 months ago - Voyager Presents Robust Preclinical Data from Tau Targeting Gene Therapy and Antibody Programs at AD/PD™ 2025 - GlobeNewsWire
- 5 months ago - Voyager Therapeutics, Inc. (VYGR) Q4 2024 Earnings Call Transcript - Seeking Alpha